Journal ArticleDOI
Self-Assembly of an Amphiphilic Janus Camptothecin-Floxuridine Conjugate into Liposome-Like Nanocapsules for More Efficacious Combination Chemotherapy in Cancer.
Reads0
Chats0
TLDR
It is shown that JCFC NCs consistently provide synergy and avoid antagonism in a broad panel of tumor cell lines, and can be extended to other hydrophilic and hydrophobic anticancer drugs that are coupled to pentaerythritol to self‐assemble into nanocapsules for drug self‐delivery, pointing to potential clinical translation in near future.Abstract:
The combination of camptothecin (CPT) and fluoropyrimidine derivatives acts synergistically at a 1:1 molar ratio. Practically, the greatest challenge is the development of a single liposomal formulation that can both encapsulate and maintain this drug combination at an exact 1:1 ratio to achieve coordinated pharmacokinetics. Consequently, a new type of liposome-like nanocapsule (NC) is developed from a highly symmetric Janus camptothecin-floxuridine conjugate (JCFC) amphiphile, which is synthesized by coupling two hydrophobic CPT molecules and two hydrophilic floxuridine (FUDR) molecules to multivalent pentaerythritol via a hydrolyzable ester linkage. JCFC NCs possess remarkably high drug-loading contents, and no premature release because of the highly stable co-delivery of the drug combination without the need for any carrier. It is shown that JCFC NCs consistently provide synergy and avoid antagonism in a broad panel of tumor cell lines. In vivo delivery of JCFC NCs leads to longer blood retention half-life, higher tumorous accumulation and cellular uptake of drugs, and greatly enhanced efficacy in murine tumor models compared to CPT, FUDR, and CPT + FUDR. This liposomal strategy can be extended to other hydrophilic and hydrophobic anticancer drugs that are coupled to pentaerythritol to self-assemble into nanocapsules for drug self-delivery, pointing to potential clinical translation in near future.read more
Citations
More filters
Journal ArticleDOI
Phage-guided modulation of the gut microbiota of mouse models of colorectal cancer augments their responses to chemotherapy.
TL;DR: Dextran nanoparticles loaded with a chemotherapeutic agent and bound to phages that eliminate a pro-tumoural gut bacterium and promote the growth of anticancer-compound-producing bacteria boost chemotherapy responses in mouse models of colorectal cancer.
Journal ArticleDOI
Combinational strategy for high-performance cancer chemotherapy.
TL;DR: This review surveys the most recent advances in combination therapy including combination chemotherapy, chemotherapy plus gene therapy, chemotherapyplus phototherapy, as well as chemotherapy plus immunotherapy, which might provide new guidelines for high-performance cancer treatments.
Journal ArticleDOI
Redox/pH dual-stimuli responsive camptothecin prodrug nanogels for "on-demand" drug delivery
Ying Qu,Bingyang Chu,Xiawei Wei,Minyi Lei,Danrong Hu,Ruoyu Zha,Lin Zhong,Mengyao Wang,Fangfang Wang,Zhiyong Qian +9 more
TL;DR: The prepared P(CPT‐MAA) prodrug nanogels exhibited superior antitumor activity both in vitro and in vivo without observed side effects, and may be a promise delivery system for chemotherapeutic agents.
Journal ArticleDOI
Mitochondria and plasma membrane dual-targeted chimeric peptide for single-agent synergistic photodynamic therapy
Hong Cheng,Rong-Rong Zheng,Gui-Ling Fan,Jing-Hao Fan,Lin-Ping Zhao,Xue-Yan Jiang,Bin Yang,Xi-Yong Yu,Shi-Ying Li,Xian-Zheng Zhang +9 more
TL;DR: The single-agent self-delivery system with dual-targeting strategy was demonstrated to be a promising nanoplatform for synergistic tumor therapy and could achieve the therapeutic effect maximization with reduced side effects.
Journal ArticleDOI
Stimulus-Responsive Sequential Release Systems for Drug and Gene Delivery.
Sepideh Ahmadi,Navid Rabiee,Mojtaba Bagherzadeh,Faranak Elmi,Faranak Elmi,Yousef Fatahi,Fatemeh Farjadian,Nafiseh Baheiraei,Behzad Nasseri,Behzad Nasseri,Mohammad Rabiee,Niloufar Tavakoli Dastjerd,Ali Valibeik,Mahdi Karimi,Michael R. Hamblin,Michael R. Hamblin +15 more
TL;DR: The key objective of this review is to summarize recent progress in SR-based drug/gene delivery systems for cancer and other diseases.
References
More filters
Journal ArticleDOI
Recent advances with liposomes as pharmaceutical carriers.
TL;DR: For further successful development of this field, promising trends must be identified and exploited, albeit with a clear understanding of the limitations of these approaches.
Journal ArticleDOI
Diffusion of Univalent Ions Across the Lamellae of Swollen Phospholipids
TL;DR: It is found that as the surface charge of the lipid lamellae is increased, the amount of cation per μmle of lipid increases, and the phospholipid liquid crystalline structures appear to “bind” or “capture” cations.
Journal ArticleDOI
Therapeutic Nanoparticles for Drug Delivery in Cancer
TL;DR: In this paper, the authors proposed a passive targeting mechanism, active targeting strategies using ligands or antibodies directed against selected tumor targets amplify the specificity of these therapeutic nanoparticles, enabling them to carry their loaded active drugs to cancer cells by selectively using the unique pathophysiology of tumors.
Journal Article
Therapeutic Nanoparticles for Drug Delivery in Cancer
TL;DR: Multifunctional and multiplex nanoparticles are now being actively investigated and are on the horizon as the next generation of nanoparticles, facilitating personalized and tailored cancer treatment.
Journal ArticleDOI
Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes
TL;DR: The PEG‐PE's activity to prolong the circulation time of liposomes is greater than that of the ganglioside GM1, awell‐described glycolipid with this activity.